Working… Menu
Trial record 1 of 1 for:    NCT01289847
Previous Study | Return to List | Next Study

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01289847
Recruitment Status : Completed
First Posted : February 4, 2011
Results First Posted : December 23, 2014
Last Update Posted : December 23, 2014
Information provided by (Responsible Party):
Bio Products Laboratory

Brief Summary:
The main objective is to determine the efficacy of Gammaplex by measuring the number of serious acute bacterial infections during treatment with Gammaplex over a 12 month period. The secondary objectives are to assess the safety and tolerability of Gammaplex and to compare the data collected from adult subjects with PID from the GMX01 study

Condition or disease Intervention/treatment Phase
Primary Immune Deficiency Disorders Common Variable Immunodeficiency X-linked Agammaglobulinemia Hyper-IgM Syndrome Wiskott-Aldrich Syndrome Biological: Gammaplex Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Study Start Date : March 2011
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: Gammaplex Biological: Gammaplex
GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 12 months ]
    Number of subjects with serious, acute, bacterial infections as a measure of efficacy

Secondary Outcome Measures :
  1. Therapeutic Efficacy [ Time Frame: From week 15 onwards ]
    Number and proportion of subjects who maintain trough IgG levels at least as high as the average of the 2 previous trough levels before the first Gammaplex infusion

  2. Therapeutic Efficacy [ Time Frame: 12 months ]
    Number of days off school

  3. Therapeutic Efficacy [ Time Frame: 12 months ]
    Number of days in hospital

  4. Therapeutic Efficacy [ Time Frame: 12 months ]
    Visits to physicians and/or emergency room

  5. Therapeutic Efficacy [ Time Frame: 12 months ]
    Number of days on therapeutic antibiotics

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is between the ages of or is equal to 2 and 16 years of age, of either sex, belonging to any ethnic group, and above a minimum weight of 10 kg. This weight is based on the amount of blood required for testing.
  • The subject has a primary immunodeficiency disease, which has as a significant component of hypogammaglobulinemia and/or antibody deficiency (e.g. common variable immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-IgM syndrome, Wiskott-Aldrich Syndrome). NB Isolated deficiency of a single IgG subclass, or of specific antibodies without hypogammaglobulinemia per se, does not qualify for inclusion.
  • Subjects already receiving IGIV replacement therapy require the following before their first infusion of Gammaplex:
  • Documented IGIV dose(s) and treatment intervals for the last 2 consecutive routine IGIV treatments (one of which can be the screening visit result). The previous doses should also meet the following conditions before study entry: Have not changed by ± 50% of the mean dose for at least 3 months; be between 300 and 800 mg/kg/infusion; be given every 21-28 days, inclusive; be a licensed or investigational product (Phase III or IIIb).
  • Documented previous IgG trough levels for the last 2 consecutive routine IGIV treatments for the last 2 consecutive routine IGIV treatments: Maintained at least 300 mg/dL above baseline serum IgG levels (defined as before initiation of any gamma globulin treatment for that subject); must be more than/equal to 600 mg/dL.
  • If a subject is a female of child-bearing potential, she must have a negative result on an HCG-based pregnancy test.
  • If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.
  • The subject is willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
  • The subject, if old enough (generally 6 years to 16), has signed a Child Assent Form and the subject's parent or legal guardian has signed the Informed Consent Form, both approved by the IEC/IRB.

Exclusion Criteria:

  • Has not been treated with IGIV (treatment naive subject)
  • The subject has a history of any severe anaphylactic reaction to blood or any blood-derived product.
  • The subject is known to be intolerant to any component of Gammaplex, such as sorbitol (i.e. intolerance to fructose).
  • The subject has selective IgA deficiency, history of reaction to products containing IgA, or has a history of antibodies to IgA.
  • Subjects who have completed the study and subjects who have withdrawn cannot participate in the study for a second time.
  • The subject is currently receiving, or has received, any investigational agent, other than an immune serum globulin (ISG) preparation that is being evaluated in a Phase III or IIIb study, within the prior 3 months.
  • The subject has been exposed to blood or any blood product or derivative within the last 6 months, other than a commercially available IGIV or other forms of commercially available and licensed ISG. If an unlicensed ISG product that is in Phase III or IIIb has been given, the subject cannot be infused with Gammaplex until 20 days after the last dose was given.
  • The subject is pregnant or is nursing.
  • The subject, at screening, has levels greater than 2.5 times the upper limit of normal as defined at the central laboratory of any of the following: (Alanine transaminase (ALT); Aspartate transaminase (AST) Lactate dehydrogenase (LDH)).
  • The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.
  • The subject is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs, or has done so within the past 12 months.
  • The subject has a history of DVT, or thrombotic complications of IGIV therapy.
  • The subject suffers from any acute or chronic medical condition (e.g. renal disease or predisposing conditions for renal disease, or protein losing state) that, in the opinion of the investigator, may interfere with the conduct of the study.
  • The subject has an acquired medical condition, such as, chronic or recurrent neutropenia (ANC < 1000 x 109/L) or AIDS known to cause secondary immune deficiency, or is post or recovering from hematopoietic stem cell transplantation.
  • The subject is receiving the following medication: Systemic long-term corticosteroids (i.e. not intermittent or burst, daily, >1 mg of prednisone equivalent/kg/day).
  • The subject is receiving Immunosuppressive or Immunomodulatory drugs.
  • The subject has non-controlled arterial hypertension.
  • The subject has anemia (hemoglobin <10 g/dL) at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01289847

Layout table for location information
United States, California
Department of Medicine, University of California
Irvine, California, United States, 92697.
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
United States, Colorado
IMMUNOe International Reseach Centers
Centennial, Colorado, United States, 80112
United States, Georgia
Family Allergy & Asthma Center, PC
Atlanta,, Georgia, United States, 30342
United States, Illinois
Rush University Medical Center
Chicago,, Illinois, United States, 60612
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
Allergy, Asthma & Immunology Clinic, P.A
Irving, Texas, United States, 75063
United States, Virginia
Children's Hospital of Richmond, VA
Richmond, Virginia, United States, 23219
Hospital de Niňos Roberto del Río
Santiago, Chile, 8380418
Safra Children's Hospital, Sheba Medical Center
Tel-Hashomer, Israel, 52621
Sponsors and Collaborators
Bio Products Laboratory
Layout table for investigator information
Study Director: Tim J. Aldwinckle, MD Medical Director
Layout table for additonal information
Responsible Party: Bio Products Laboratory Identifier: NCT01289847    
Other Study ID Numbers: GMX04
IND 12569 ( Registry Identifier: CBER )
First Posted: February 4, 2011    Key Record Dates
Results First Posted: December 23, 2014
Last Update Posted: December 23, 2014
Last Verified: December 2014
Keywords provided by Bio Products Laboratory:
Primary Immune Deficiency Disorders
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Hyper-IgM syndrome
Wiskott-Aldrich Syndrome
Bacterial Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Wiskott-Aldrich Syndrome
Hyper-IgM Immunodeficiency Syndrome
Hyper-IgM Immunodeficiency Syndrome, Type 1
Immunologic Deficiency Syndromes
Common Variable Immunodeficiency
Pathologic Processes
Immune System Diseases
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhagic Disorders
Leukocyte Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Blood Protein Disorders
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs